Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

Plain-language summary

This study examines the effect of Elexacaftor-Tezacaftor-Ivacaftor (ETI) treatment on metabolic, epigenetic, and fecal microbiota profiles in people with cystic fibrosis. People of any age with cystic fibrosis who are about to start ETI therapy can take part. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Meyer Children's Hospital IRCCS

Intervention

Elexacaftor, Tezacaftor, Ivacaftor

Start date

12/2/2025

Estimated completion

4/30/2029

Countries

Italy

Related genes

Locations

• Bari, Italy
• Milan, Italy
• Naples, Italy
• Roma, Italy
• Torino, Italy
• Florence, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients with CF, of any age, about to start ETI therapy, in accordance with marketing authorization Italian legislative directives, followed at the participating CF centers.
* Obtaining informed consent.

Exclusion Criteria:

* CF patients not in ETI therapy and CF patients already in ETI therapy.